Diagnosis of von Willebrand disease subtypes: Implications for treatment

Haemophilia

Volumn 14, Issue SUPPL. 5, 2008, Pages 27-38

  Budde, Ulrich ^a  

^a Coagulation Laboratory   (Germany)

Author keywords

Classification; Subtypes; Von Willebrand factor; Von Willebrand factor multimers; Vvon Willebrand disease

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; DESMOPRESSIN; POLYMER; RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANAMNESIS; BLEEDING DISORDER; BLOOD CLOTTING TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIMERIZATION; DISEASE CLASSIFICATION; FAMILY HISTORY; HUMAN; LABORATORY TEST; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR OCCUPANCY; REVIEW; SCREENING; STANDARD; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

DIAGNOSIS, DIFFERENTIAL; FACTOR VIII; HUMANS; MUTATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 51349101279     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01849.x     Document Type: Review

References (45)

1. Ruggeri ZM. Classification of von Willebrand disease. In: Verstraete M, Vermylen J, Lijnen R, Arnout J eds. Thrombosis and Haemostasis. Leuven: Leuven University Press, 1987: 419-45.
2. Sadler EJ. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
3. Sadler JE, Budde U, Eikenboom JCJ et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
4. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
5. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-64.
6. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. J Clin Invest 1973; 52: 2708-16.
7. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Thromb Haemost 1999; 82: 1276-82.
8. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.
9. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
10. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
11. Favaloro E. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127-35.
12. Howard MA, Firkin BG. Ristocetin - a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
13. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302: 1047-51.
14. Hilbert L, Jenkins PV, Gaucher C et al. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb Haemost 2000; 84: 188-94.
15. Nitu-Whalley IC, Riddell A, Lee CA et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: A reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
16. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998; 80: 37-41.
17. van Genderen PJJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80: 495-8.
18. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
19. Bukh A, Ingerslev J, Stenbjerg S, Hundahl Möller NP. The multimeric structure of plasma F VIII:RAg studied by electroelution and immunoperoxidase detection. Thromb Res 1986; 43: 579-84.
20. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5.
21. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-57.
22. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 947-51.
23. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14: 337-47.
24. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
25. Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction. J Biol Chem 1991; 266: 13499-502.
26. Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
27. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
28. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-54.
29. Cumming A, Grundy P, Keeney S et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-41.
30. Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63: 1369-71.
31. Ruggeri ZM, Nilsson IM, Lombardi R, Holmberg L, Zimmerman TS. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest 1982; 70: 1124-7.
32. Ledford MR, Rabinowitz I, Sadler JE, Kent JW, Civantos F. New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: Von Willebrand disease type IIC Miami. Blood 1993; 82: 169-75.
33. Schneppenheim R, Obser T, Schneppenheim S, Mainusch K, Angerhaus D, Budde U. Von Willebrand disease type 2A with aberrant structure of individual oligomers is caused by mutations clustering in the von Willebrand factor D3 domain. Blood 2000; 96: 566a.
34. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type-IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
35. Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 149-56.
36. Holmberg L, Berntorp E, Donner M, Nilsson IM. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68: 668-72.
37. Jorieux S, Gaucher C, Goudemand J, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood 1998; 92: 4663-70.
38. Schneppenheim R, Lenk H, Obser T et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: Characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92: 36-41.
39. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
40. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and treatment of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
41. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1-159.
42. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-9.
43. Kunicki TJ, Federici AB, Salomon DR et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 104: 2359-67.
44. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease. Results of a multicenter European study. Blood 2004; 103: 2032-8.
45. Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: A 2004 update. Semin Hematol 2005; 42: 15-28.